Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a study in par...
Read more -
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
Read more -
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
U.S. FDA accepts GSK’s sNDA application for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Read more -
FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States
U.S. FDA has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an OTC product
Read more -
GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)
Total EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1% CER
Read more -
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
Read more -
GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development
GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.
Read more -
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients
Read more -
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.
Read more -
Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)
GlaxoSmithKline plc today announced that Deborah Waterhouse, CEO of ViiV Healthcare, will join GSK’s Corporate Executive Team
Read more -
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare received a CRL from the FDA regarding its application for cabotegravir and rilpivirine.
Read more -
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
BLISS-LN achieves primary endpoint and all major secondary endpoints. On-track for regulatory submission during the first half of 2020.
Read more -
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
GSK announced treatment with the investigational single-agent belantamab mafodotin
Read more -
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
ViiV files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
Read more -
GSK employees celebrate #GivingTuesday with $190,000 in awards to local nonprofits
GSK announced on #GivingTuesday that its employees have selected 19 local nonprofit organizations to each receive $10,000 charitable gifts to support their work making communiti...
Read more -
GSK awarding $400,000 to Greater Philadelphia nonprofits making an IMPACT on health outcomes
GSK today honored 10 local nonprofits that help foster a healthier Philadelphia region.
Read more -
GSK awards Triangle nonprofits making a powerful IMPACT on health outcomes
Ten North Carolina nonprofits will each receive a $40,000 GSK IMPACT Award
Read more -
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
Read more -
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic. Investigating use for uncomplicated urinary tract infect...
Read more -
GSK receives prestigious Prix Galien USA award for SHINGRIX
SHINGRIX recognized as 2019 Best Pharmaceutical Product, following Galien Award win in Germany last week, acknowledging the health impact of innovative vaccine
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
